Biotech News
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
Statistically significant (p
Open original release
Related news
ORGOOrganogenesis2026-06-25 13:46 EST
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
ORGOOrganogenesis2026-06-25 13:46 EST
Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORGOOrganogenesis2026-06-25 13:46 EST
Organogenesis Applauds CMS’s Significant Step In Payment Reform
ORGOOrganogenesis2026-06-25 13:46 EST
Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance
ORGOOrganogenesis2026-06-25 13:46 EST
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
ORGOOrganogenesis2026-06-25 13:46 EST
Organogenesis Announces Initiation of Biologics License Application for ReNu®
ORGOOrganogenesis2026-06-25 13:46 EST
Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
ORGOOrganogenesis2026-06-25 13:46 EST
Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
ORGOOrganogenesis2026-06-25 13:46 EST
Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2026 Financial Results on May 7, 2026
ORGOOrganogenesis2026-06-25 13:46 EST
Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®
Organogenesis
Organogenesis is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Recent company news
ORGOOrganogenesis2026-06-26 10:40 EST
Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
ORGOOrganogenesis2026-06-26 10:40 EST
Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORGOOrganogenesis2026-06-26 10:40 EST
Organogenesis Applauds CMS’s Significant Step In Payment Reform
ORGOOrganogenesis2026-06-26 10:40 EST
Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance
ORGOOrganogenesis2026-06-26 10:40 EST
Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
Stock data
- Close
- —
- Market cap
- —
- Exchange
- NASDAQ
- Sector
- Biotechnology
- Location
- United States